Teams that bring a variety of experience and expertise can spot problems faster and arrive at more well-rounded, viable ...

Biotechnology company Moderna (NASDAQ:MRNA) announced better-than-expected revenue in Q2 CY2025, but sales fell by 41.1% year ...

Moderna’s second quarter results were met with a negative market reaction, as investors focused on both a sharp decline in ...

Dublin, Aug. 12, 2025 (GLOBE NEWSWIRE) -- The "Neoantigen Cancer Vaccine Market by Neoantigen Type (Personalized Neoantigens, Shared Neoantigens), Therapeutic Target (Immune Checkpoint Blockade, Tumor ...

When COVID-19 cases were surging, Dr. David Wohl saw patients “hungry for air” fill UNC hospital wards. What most saved lives, he said, were vaccines developed with unprecedented speed using mRNA ...

Scientists used IBM's R2 Heron quantum processor to predict the secondary protein structure of a 60-nucleotide-long mRNA ...

So-called mRNA vaccines saved millions of lives during the COVID-19 pandemic — and now scientists are using that Nobel Prize-winning technology to try to develop vaccines and treatments against ...

Germany's CureVac and Britain's GSK have settled a years-long patent dispute with Pfizer and its partner BioNTech over the ...

mRNA expert Jeff Coller spoke with Live Science about the future of mRNA vaccines in the United States in the aftermath of huge federal funding cuts.

HHS cancels $776M Moderna contract for avian flu vaccine, signaling a major change in vaccine research approach.

The COVID-19 vaccines made with mRNA by Pfizer and Moderna can be updated more quickly each year than traditional types, and researchers are already testing an mRNA-based therapeutic vaccine for ...